All articles by Aninda Chakraborty

  1. WuXi Biologics to acquire drug manufacturing plant in Germany

    WuXi Biologics has signed an acquisition agreement to take over a Bayer’s drug product manufacturing plant in Leverkusen, Germany. The…
    Read More…

    17 Jan
  2. Novo Nordisk secures FDA expanded indication for Ozempic

    The US Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk’s Ozempic (semaglutide). The once-weekly injection…
    Read More…

    17 Jan
  3. Merck closes $2.7bn acquisition of biopharmaceutical firm ArQule

    Merck (MSD) has completed its previously announced acquisition of US-based biopharmaceutical company ArQule. The $2.7bn deal closed following completion of…
    Read More…

    17 Jan
  4. Dermavant licences Tapinarof commercial rights in Japan

    Dermavant Sciences, a subsidiary of Roivant Sciences, has signed an exclusive agreement to licence the development and commercial rights of…
    Read More…

    16 Jan
  5. BMS secures FDA priority review for NSCLC treatment combination

    Bristol-Myers Squibb Company (BMS) has secured the US Food and Drug Administration (FDA) priority review for a drug combination to…
    Read More…

    16 Jan
  6. Galapagos expands fibrosis research collaboration with Fibrocor

    Galapagos has expanded its research collaboration with Candian firm Fibrocor Therapeutics, which develops tissue-specific therapeutics for fibrotic diseases. Under the…
    Read More…

    16 Jan
  7. Takeda partners Charles River to develop preclinical candidates

    Takeda Pharmaceutical Company has teamed up with Charles River to deliver preclinical candidates across its four core therapeutic areas. Under…
    Read More…

    14 Jan
  8. Coherus signs in-licensing agreement for Avastin biosimilar

    Coherus BioSciences has signed an in-licensing agreement to acquire commercial rights of Innovent Biologics’ biosimilar candidate to Avastin (bevacizumab) (IBI305)…
    Read More…

    14 Jan
  9. FDA grants priority review for AstraZeneca’s Lynparza

    The US Food and Drug Administration (FDA) has granted priority review for Lynparza (olaparib) in combination with bevacizumab to treat…
    Read More…

    14 Jan
  10. Iovance Biotherapeutics secures IOV-3001 licencing from Novartis

    Iovance Biotherapeutics has secured the licence to develop and commercialise IOV-3001, an antibody cytokine engrafted protein, from Novartis. As agreed,…
    Read More…

    13 Jan
Close
Close
Close

Go Top